Comparing Dosing and Management of BCMA vs Non-BCMA Bispecific Antibodies

Opinion
Video

Panelists discuss how the evaluation and treatment initiation processes for non-BCMA targeted bispecifics and BCMA-targeted bispecifics share core similarities in patient assessment and care coordination, but differ in specific premedication protocols, dosing strategies, and side effect management.

Video Player is loading.
Current Time 0:00
Duration 0:00
Loaded: 0%
Stream Type LIVE
Remaining Time 0:00
 
1x
    • Chapters
    • descriptions off, selected
    • captions off, selected

      Video content above is prompted by the following:

      • Is the process different/similar for patients who might be receiving non-BCMA targeted bispecific vs BCMA-bispecific?
      • Review any differences/similarities between bispecifics (non-BCMA vs BCMA) for step up dosing, premedication/prophylaxis, etc.
      Related Content